Treace Medical Concepts, Inc.

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TMCI is priced at $3.40, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TMCI's ROE is -0.69%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BSX-PA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ABT has a market cap of 150.3B. Regarding current trading prices, TMCI is priced at $3.40, while ABT trades at $85.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ABT's P/E ratio is 24.16. In terms of profitability, TMCI's ROE is -0.69%, compared to ABT's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ABT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ISRG has a market cap of 150B. Regarding current trading prices, TMCI is priced at $3.40, while ISRG trades at $422.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ISRG's P/E ratio is 51.41. In terms of profitability, TMCI's ROE is -0.69%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, TMCI is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ISRG's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SYK has a market cap of 117.9B. Regarding current trading prices, TMCI is priced at $3.40, while SYK trades at $307.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SYK's P/E ratio is 35.59. In terms of profitability, TMCI's ROE is -0.69%, compared to SYK's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SYK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, MDT has a market cap of 97B. Regarding current trading prices, TMCI is priced at $3.40, while MDT trades at $74.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas MDT's P/E ratio is 21.11. In terms of profitability, TMCI's ROE is -0.69%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check MDT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BSX has a market cap of 73B. Regarding current trading prices, TMCI is priced at $3.40, while BSX trades at $48.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BSX's P/E ratio is 20.55. In terms of profitability, TMCI's ROE is -0.69%, compared to BSX's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BSX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BRKRP has a market cap of 61.7B. Regarding current trading prices, TMCI is priced at $3.40, while BRKRP trades at $434.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BRKRP's P/E ratio is N/A. In terms of profitability, TMCI's ROE is -0.69%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, TMCI is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BRKRP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, TMCI is priced at $3.40, while EW trades at $86.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas EW's P/E ratio is 46.46. In terms of profitability, TMCI's ROE is -0.69%, compared to EW's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check EW's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, RMD has a market cap of 29.5B. Regarding current trading prices, TMCI is priced at $3.40, while RMD trades at $194.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas RMD's P/E ratio is 19.60. In terms of profitability, TMCI's ROE is -0.69%, compared to RMD's ROE of +0.24%. Regarding short-term risk, TMCI is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check RMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, DXCM has a market cap of 27.9B. Regarding current trading prices, TMCI is priced at $3.40, while DXCM trades at $73.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas DXCM's P/E ratio is 31.05. In terms of profitability, TMCI's ROE is -0.69%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, TMCI is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check DXCM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PHG has a market cap of 25.2B. Regarding current trading prices, TMCI is priced at $3.40, while PHG trades at $26.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PHG's P/E ratio is 22.81. In terms of profitability, TMCI's ROE is -0.69%, compared to PHG's ROE of +0.09%. Regarding short-term risk, TMCI is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PHG's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, STE has a market cap of 21.1B. Regarding current trading prices, TMCI is priced at $3.40, while STE trades at $212.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas STE's P/E ratio is 27.13. In terms of profitability, TMCI's ROE is -0.69%, compared to STE's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check STE's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TMCI is priced at $3.40, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TMCI's ROE is -0.69%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ABMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ZBH has a market cap of 16B. Regarding current trading prices, TMCI is priced at $3.40, while ZBH trades at $82.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ZBH's P/E ratio is 21.46. In terms of profitability, TMCI's ROE is -0.69%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, TMCI is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ZBH's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, TMCI is priced at $3.40, while SNN trades at $29.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SNN's P/E ratio is 20.81. In terms of profitability, TMCI's ROE is -0.69%, compared to SNN's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SNN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TMCI is priced at $3.40, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TMCI's ROE is -0.69%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, TMCI is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SWAV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, TMCI is priced at $3.40, while PEN trades at $318.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PEN's P/E ratio is 73.67. In terms of profitability, TMCI's ROE is -0.69%, compared to PEN's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PEN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, TMCI is priced at $3.40, while ALGN trades at $177.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ALGN's P/E ratio is 29.07. In terms of profitability, TMCI's ROE is -0.69%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ALGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, TMCI is priced at $3.40, while GMED trades at $82.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas GMED's P/E ratio is 19.27. In terms of profitability, TMCI's ROE is -0.69%, compared to GMED's ROE of +0.13%. Regarding short-term risk, TMCI is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check GMED's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, TMCI is priced at $3.40, while PODD trades at $142.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PODD's P/E ratio is 33.33. In terms of profitability, TMCI's ROE is -0.69%, compared to PODD's ROE of +0.21%. Regarding short-term risk, TMCI is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PODD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, MASI has a market cap of 9.3B. Regarding current trading prices, TMCI is priced at $3.40, while MASI trades at $178.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas MASI's P/E ratio is 44.17. In terms of profitability, TMCI's ROE is -0.69%, compared to MASI's ROE of +0.09%. Regarding short-term risk, TMCI is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check MASI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BIO has a market cap of 8.6B. Regarding current trading prices, TMCI is priced at $3.40, while BIO trades at $314.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BIO's P/E ratio is 53.00. In terms of profitability, TMCI's ROE is -0.69%, compared to BIO's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BIO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BRKR has a market cap of 8.3B. Regarding current trading prices, TMCI is priced at $3.40, while BRKR trades at $58.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BRKR's P/E ratio is -226.62. In terms of profitability, TMCI's ROE is -0.69%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, TMCI is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check BRKR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, TMCI is priced at $3.40, while BIO-B trades at $304.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BIO-B's P/E ratio is 50.52. In terms of profitability, TMCI's ROE is -0.69%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BIO-B's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, GKOS has a market cap of 6.3B. Regarding current trading prices, TMCI is priced at $3.40, while GKOS trades at $104.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas GKOS's P/E ratio is -32.36. In terms of profitability, TMCI's ROE is -0.69%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, TMCI is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check GKOS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TMCI is priced at $3.40, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas NARI's P/E ratio is -59.24. In terms of profitability, TMCI's ROE is -0.69%, compared to NARI's ROE of -0.00%. Regarding short-term risk, TMCI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NARI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, TMCI is priced at $3.40, while LIVN trades at $73.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas LIVN's P/E ratio is 37.27. In terms of profitability, TMCI's ROE is -0.69%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, TMCI is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check LIVN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, TMCI is priced at $3.40, while IRTC trades at $115.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas IRTC's P/E ratio is -136.01. In terms of profitability, TMCI's ROE is -0.69%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IRTC's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TMCI is priced at $3.40, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TMCI's ROE is -0.69%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TMCI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AXNX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, TMCI is priced at $3.40, while ITGR trades at $90.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ITGR's P/E ratio is 22.33. In terms of profitability, TMCI's ROE is -0.69%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, TMCI is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ITGR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, TMCI is priced at $3.40, while TMDX trades at $67.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas TMDX's P/E ratio is 15.52. In terms of profitability, TMCI's ROE is -0.69%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, TMCI is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check TMDX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AXGN has a market cap of 2.1B. Regarding current trading prices, TMCI is priced at $3.40, while AXGN trades at $39.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AXGN's P/E ratio is -63.16. In terms of profitability, TMCI's ROE is -0.69%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AXGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, TMCI is priced at $3.40, while ESTA trades at $72.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ESTA's P/E ratio is -49.65. In terms of profitability, TMCI's ROE is -0.69%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, TMCI is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ESTA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TMCI is priced at $3.40, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TMCI's ROE is -0.69%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TMCI is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NUVA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, TMCI is priced at $3.40, while UFPT trades at $225.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas UFPT's P/E ratio is 25.97. In terms of profitability, TMCI's ROE is -0.69%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, TMCI is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check UFPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, TMCI is priced at $3.40, while PRCT trades at $26.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PRCT's P/E ratio is -14.86. In terms of profitability, TMCI's ROE is -0.69%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, TMCI is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PRCT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, TMCI is priced at $3.40, while AHCO trades at $10.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AHCO's P/E ratio is -17.54. In terms of profitability, TMCI's ROE is -0.69%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, TMCI is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AHCO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, TMCI is priced at $3.40, while ENOV trades at $22.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ENOV's P/E ratio is -1.16. In terms of profitability, TMCI's ROE is -0.69%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, TMCI is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ENOV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TMCI is priced at $3.40, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TMCI's ROE is -0.69%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TMCI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check HSKA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, TMCI is priced at $3.40, while IART trades at $16.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas IART's P/E ratio is -2.54. In terms of profitability, TMCI's ROE is -0.69%, compared to IART's ROE of -0.48%. Regarding short-term risk, TMCI is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IART's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $3.40, while INSP trades at $42.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas INSP's P/E ratio is 9.80. In terms of profitability, TMCI's ROE is -0.69%, compared to INSP's ROE of +0.18%. Regarding short-term risk, TMCI is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INSP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $3.40, while ATEC trades at $7.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ATEC's P/E ratio is -9.51. In terms of profitability, TMCI's ROE is -0.69%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, TMCI is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ATEC's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $3.40, while BFLY trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BFLY's P/E ratio is -15.37. In terms of profitability, TMCI's ROE is -0.69%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, TMCI is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BFLY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $3.40, while IRMD trades at $93.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas IRMD's P/E ratio is 50.38. In terms of profitability, TMCI's ROE is -0.69%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, TMCI is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IRMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $3.40, while AVNS trades at $24.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AVNS's P/E ratio is -15.48. In terms of profitability, TMCI's ROE is -0.69%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, TMCI is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AVNS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $3.40, while TNDM trades at $17.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas TNDM's P/E ratio is -12.20. In terms of profitability, TMCI's ROE is -0.69%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, TMCI is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check TNDM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $3.40, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SILK's P/E ratio is -18.96. In terms of profitability, TMCI's ROE is -0.69%, compared to SILK's ROE of -0.35%. Regarding short-term risk, TMCI is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SILK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $3.40, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas FNA's P/E ratio is -19.83. In terms of profitability, TMCI's ROE is -0.69%, compared to FNA's ROE of -0.35%. Regarding short-term risk, TMCI is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check FNA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $3.40, while AORT trades at $22.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AORT's P/E ratio is 90.24. In terms of profitability, TMCI's ROE is -0.69%, compared to AORT's ROE of +0.03%. Regarding short-term risk, TMCI is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AORT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $3.40, while CNMD trades at $35.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CNMD's P/E ratio is 20.08. In terms of profitability, TMCI's ROE is -0.69%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, TMCI is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CNMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, INMD has a market cap of 890.2M. Regarding current trading prices, TMCI is priced at $3.40, while INMD trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas INMD's P/E ratio is 10.41. In terms of profitability, TMCI's ROE is -0.69%, compared to INMD's ROE of +0.13%. Regarding short-term risk, TMCI is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TMCI is priced at $3.40, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CSII's P/E ratio is -20.83. In terms of profitability, TMCI's ROE is -0.69%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TMCI is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CSII's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SSII has a market cap of 790.5M. Regarding current trading prices, TMCI is priced at $3.40, while SSII trades at $3.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SSII's P/E ratio is -79.00. In terms of profitability, TMCI's ROE is -0.69%, compared to SSII's ROE of -0.23%. Regarding short-term risk, TMCI is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SSII's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, LMRI has a market cap of 739.8M. Regarding current trading prices, TMCI is priced at $3.40, while LMRI trades at $7.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas LMRI's P/E ratio is -20.81. In terms of profitability, TMCI's ROE is -0.69%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, TMCI is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check LMRI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, TMCI is priced at $3.40, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CRY's P/E ratio is 425.71. In terms of profitability, TMCI's ROE is -0.69%, compared to CRY's ROE of +0.03%. Regarding short-term risk, TMCI is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CRY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CBLL has a market cap of 708.4M. Regarding current trading prices, TMCI is priced at $3.40, while CBLL trades at $18.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CBLL's P/E ratio is -11.52. In terms of profitability, TMCI's ROE is -0.69%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, TMCI is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CBLL's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SIBN has a market cap of 639.1M. Regarding current trading prices, TMCI is priced at $3.40, while SIBN trades at $14.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SIBN's P/E ratio is -36.95. In terms of profitability, TMCI's ROE is -0.69%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, TMCI is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SIBN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BWAY has a market cap of 622.9M. Regarding current trading prices, TMCI is priced at $3.40, while BWAY trades at $15.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BWAY's P/E ratio is 72.18. In terms of profitability, TMCI's ROE is -0.69%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BWAY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, TMCI is priced at $3.40, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SRDX's P/E ratio is -34.66. In terms of profitability, TMCI's ROE is -0.69%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, TMCI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SRDX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BVS has a market cap of 600.9M. Regarding current trading prices, TMCI is priced at $3.40, while BVS trades at $8.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BVS's P/E ratio is 21.63. In terms of profitability, TMCI's ROE is -0.69%, compared to BVS's ROE of +0.16%. Regarding short-term risk, TMCI is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BVS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, NPCE has a market cap of 592.9M. Regarding current trading prices, TMCI is priced at $3.40, while NPCE trades at $17.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas NPCE's P/E ratio is -26.35. In terms of profitability, TMCI's ROE is -0.69%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, TMCI is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NPCE's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CERS has a market cap of 585.1M. Regarding current trading prices, TMCI is priced at $3.40, while CERS trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CERS's P/E ratio is -58.40. In terms of profitability, TMCI's ROE is -0.69%, compared to CERS's ROE of -0.15%. Regarding short-term risk, TMCI is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check CERS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TMCI is priced at $3.40, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas APEN's P/E ratio is -9.43. In terms of profitability, TMCI's ROE is -0.69%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TMCI is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check APEN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, TCMD has a market cap of 576.3M. Regarding current trading prices, TMCI is priced at $3.40, while TCMD trades at $25.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas TCMD's P/E ratio is 29.37. In terms of profitability, TMCI's ROE is -0.69%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check TCMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, TMCI is priced at $3.40, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, TMCI's ROE is -0.69%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, TMCI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ZIMV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CTKB has a market cap of 532.1M. Regarding current trading prices, TMCI is priced at $3.40, while CTKB trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CTKB's P/E ratio is -7.10. In terms of profitability, TMCI's ROE is -0.69%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CTKB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, KIDS has a market cap of 457.4M. Regarding current trading prices, TMCI is priced at $3.40, while KIDS trades at $17.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas KIDS's P/E ratio is -10.60. In terms of profitability, TMCI's ROE is -0.69%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, TMCI is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check KIDS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PACB has a market cap of 456.6M. Regarding current trading prices, TMCI is priced at $3.40, while PACB trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PACB's P/E ratio is -3.59. In terms of profitability, TMCI's ROE is -0.69%, compared to PACB's ROE of -4.88%. Regarding short-term risk, TMCI is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check PACB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, LAB has a market cap of 445M. Regarding current trading prices, TMCI is priced at $3.40, while LAB trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas LAB's P/E ratio is -8.77. In terms of profitability, TMCI's ROE is -0.69%, compared to LAB's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check LAB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, VREX has a market cap of 442.9M. Regarding current trading prices, TMCI is priced at $3.40, while VREX trades at $10.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas VREX's P/E ratio is -5.26. In terms of profitability, TMCI's ROE is -0.69%, compared to VREX's ROE of -0.18%. Regarding short-term risk, TMCI is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check VREX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, VMD has a market cap of 383.8M. Regarding current trading prices, TMCI is priced at $3.40, while VMD trades at $9.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas VMD's P/E ratio is 26.34. In terms of profitability, TMCI's ROE is -0.69%, compared to VMD's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check VMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, OFIX has a market cap of 383.6M. Regarding current trading prices, TMCI is priced at $3.40, while OFIX trades at $9.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas OFIX's P/E ratio is -6.33. In terms of profitability, TMCI's ROE is -0.69%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, TMCI is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check OFIX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, DCTH has a market cap of 378M. Regarding current trading prices, TMCI is priced at $3.40, while DCTH trades at $10.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas DCTH's P/E ratio is 1095.00. In terms of profitability, TMCI's ROE is -0.69%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, TMCI is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check DCTH's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CLPT has a market cap of 367.1M. Regarding current trading prices, TMCI is priced at $3.40, while CLPT trades at $12.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CLPT's P/E ratio is -12.24. In terms of profitability, TMCI's ROE is -0.69%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, TMCI is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check CLPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, MASS has a market cap of 337.7M. Regarding current trading prices, TMCI is priced at $3.40, while MASS trades at $8.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas MASS's P/E ratio is -9.21. In terms of profitability, TMCI's ROE is -0.69%, compared to MASS's ROE of -0.26%. Regarding short-term risk, TMCI is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check MASS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ELMD has a market cap of 326.2M. Regarding current trading prices, TMCI is priced at $3.40, while ELMD trades at $38.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ELMD's P/E ratio is 33.68. In terms of profitability, TMCI's ROE is -0.69%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, TMCI is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ELMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, AVR has a market cap of 322.6M. Regarding current trading prices, TMCI is priced at $3.40, while AVR trades at $8.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas AVR's P/E ratio is -3.95. In terms of profitability, TMCI's ROE is -0.69%, compared to AVR's ROE of -1.24%. Regarding short-term risk, TMCI is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AVR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CATX has a market cap of 312.9M. Regarding current trading prices, TMCI is priced at $3.40, while CATX trades at $3.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CATX's P/E ratio is -2.87. In terms of profitability, TMCI's ROE is -0.69%, compared to CATX's ROE of -0.42%. Regarding short-term risk, TMCI is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CATX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, TMCI is priced at $3.40, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SMLR's P/E ratio is 3.92. In terms of profitability, TMCI's ROE is -0.69%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, TMCI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SMLR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SENS has a market cap of 280.9M. Regarding current trading prices, TMCI is priced at $3.40, while SENS trades at $6.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SENS's P/E ratio is -3.41. In terms of profitability, TMCI's ROE is -0.69%, compared to SENS's ROE of -1.30%. Regarding short-term risk, TMCI is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SENS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SGHT has a market cap of 275.3M. Regarding current trading prices, TMCI is priced at $3.40, while SGHT trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SGHT's P/E ratio is -7.23. In terms of profitability, TMCI's ROE is -0.69%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, TMCI is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SGHT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, TMCI is priced at $3.40, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas MGRM's P/E ratio is -11.11. In terms of profitability, TMCI's ROE is -0.69%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, TMCI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check MGRM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, RXST has a market cap of 231.4M. Regarding current trading prices, TMCI is priced at $3.40, while RXST trades at $5.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas RXST's P/E ratio is -4.95. In terms of profitability, TMCI's ROE is -0.69%, compared to RXST's ROE of -0.17%. Regarding short-term risk, TMCI is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check RXST's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PMI has a market cap of 229.3M. Regarding current trading prices, TMCI is priced at $3.40, while PMI trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PMI's P/E ratio is -0.19. In terms of profitability, TMCI's ROE is -0.69%, compared to PMI's ROE of +4.99%. Regarding short-term risk, TMCI is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check PMI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TMCI is priced at $3.40, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TMCI's ROE is -0.69%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TMCI is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NVRO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, TMCI is priced at $3.40, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas EYES's P/E ratio is N/A. In terms of profitability, TMCI's ROE is -0.69%, compared to EYES's ROE of -2.64%. Regarding short-term risk, TMCI is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check EYES's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, PROF has a market cap of 208.8M. Regarding current trading prices, TMCI is priced at $3.40, while PROF trades at $6.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas PROF's P/E ratio is -5.56. In terms of profitability, TMCI's ROE is -0.69%, compared to PROF's ROE of -0.71%. Regarding short-term risk, TMCI is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PROF's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, ANIK has a market cap of 198.3M. Regarding current trading prices, TMCI is priced at $3.40, while ANIK trades at $14.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas ANIK's P/E ratio is -18.86. In terms of profitability, TMCI's ROE is -0.69%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, TMCI is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ANIK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, TMCI is priced at $3.40, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas BSGM's P/E ratio is -5.81. In terms of profitability, TMCI's ROE is -0.69%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, TMCI is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check BSGM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, TMCI is priced at $3.40, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas MDGS's P/E ratio is -0.27. In terms of profitability, TMCI's ROE is -0.69%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, TMCI is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check MDGS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, INGN has a market cap of 177.1M. Regarding current trading prices, TMCI is priced at $3.40, while INGN trades at $6.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas INGN's P/E ratio is -7.19. In terms of profitability, TMCI's ROE is -0.69%, compared to INGN's ROE of -0.13%. Regarding short-term risk, TMCI is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, APYX has a market cap of 173.8M. Regarding current trading prices, TMCI is priced at $3.40, while APYX trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas APYX's P/E ratio is -18.86. In terms of profitability, TMCI's ROE is -0.69%, compared to APYX's ROE of -0.91%. Regarding short-term risk, TMCI is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check APYX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, TMCI is priced at $3.40, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas QIPT's P/E ratio is -15.87. In terms of profitability, TMCI's ROE is -0.69%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, TMCI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check QIPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, EDAP has a market cap of 157.4M. Regarding current trading prices, TMCI is priced at $3.40, while EDAP trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas EDAP's P/E ratio is -5.12. In terms of profitability, TMCI's ROE is -0.69%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, TMCI is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check EDAP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, CVRX has a market cap of 149.4M. Regarding current trading prices, TMCI is priced at $3.40, while CVRX trades at $5.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas CVRX's P/E ratio is -2.80. In terms of profitability, TMCI's ROE is -0.69%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, TMCI is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CVRX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, QTRX has a market cap of 143.7M. Regarding current trading prices, TMCI is priced at $3.40, while QTRX trades at $3.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas QTRX's P/E ratio is -1.30. In terms of profitability, TMCI's ROE is -0.69%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, TMCI is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check QTRX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, SNWV has a market cap of 143.3M. Regarding current trading prices, TMCI is priced at $3.40, while SNWV trades at $16.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas SNWV's P/E ratio is 17.35. In terms of profitability, TMCI's ROE is -0.69%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, TMCI is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SNWV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, NNOX has a market cap of 136.4M. Regarding current trading prices, TMCI is priced at $3.40, while NNOX trades at $1.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas NNOX's P/E ratio is -1.69. In terms of profitability, TMCI's ROE is -0.69%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, TMCI is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NNOX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 199.8M. In comparison, QTI has a market cap of 135.7M. Regarding current trading prices, TMCI is priced at $3.40, while QTI trades at $5.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -3.21, whereas QTI's P/E ratio is -4.67. In terms of profitability, TMCI's ROE is -0.69%, compared to QTI's ROE of -63.30%. Regarding short-term risk, TMCI is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check QTI's competition here